There are currently 29 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Autism participants are Florida, California, New York and Arizona.
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757
Recruiting
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Register for Updates
Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
NCT05837819
Recruiting
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/09/2024
Locations: Icahn School of Medicine at Mount Sinai, Albany, New York +1 locations
Conditions: Alzheimer's Disease, Sleep Disturbance
Register for Updates
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
NCT05591027
Recruiting
This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.
Gender:
All
Ages:
Between 65 years and 85 years
Trial Updated:
04/05/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Register for Updates
A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1
NCT06356337
Recruiting
The purpose of this research study is to investigate the relationship between light and circadian rhythms. Twenty healthy older adults will be recruited to participate in a randomized, cross-over study, where an active lighting intervention designed to maintain entrainment and a control intervention designed not to entrain will be tested.
Gender:
All
Ages:
55 years and above
Trial Updated:
04/04/2024
Locations: Light and Health Research Center, Menands, New York
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240
Recruiting
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/02/2024
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida +2 locations
Conditions: Alzheimer's Disease
Register for Updates
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/22/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease
Register for Updates
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/29/2024
Locations: MD First Research - Chandler, Chandler, Arizona +48 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Register for Updates
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/29/2024
Locations: MD First Research - Chandler, Chandler, Arizona +75 locations
Conditions: Alzheimer's Disease
Register for Updates
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT05744401
Recruiting
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/23/2024
Locations: Charter Research, Lady Lake, Florida +22 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
All
Ages:
Between 35 years and 85 years
Trial Updated:
02/20/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +16 locations
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
Register for Updates
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
NCT05619692
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
02/15/2024
Locations: Sage Investigational Site, Gilbert, Arizona +35 locations
Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Register for Updates
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, San Diego, California +103 locations
Conditions: Alzheimer's Disease
Register for Updates